Curative Resection of Transverse Colon Cancer via Minilaparotomy

2011 ◽  
Vol 96 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Hideyuki Ishida ◽  
Tohru Ishiguro ◽  
Keiichiro Ishibashi ◽  
Tomonori Ohsawa ◽  
Norimichi Okada ◽  
...  

Abstract Minilaparotomy has been reported to be a minimally invasive alternative to laparoscopically assisted surgery. We retrospectively evaluated the usefulness of minilaparotomy for the resection of transverse colon cancer, which has generally been considered difficult to resect laparoscopically. Patients for whom curative resection was attempted for transverse colon cancer (n  =  21) or sigmoid colon cancer (n  =  81) via minilaparotomy (skin incision, ≤ 7cm) were analyzed. The 2 groups did not significantly differ in terms of success rate of minilaparotomy (90.5% versus 97.5%), age, sex, pathologic stage, body mass index, operative time (mean, 133.5 minutes versus 122.5 minutes), blood loss (119.7 mL versus 92.4 mL), number of lymph nodes harvested, incidence of postoperative complications (9.5% versus 12.3%), postoperative length of stay, and 5-year disease-free survival rate (86.6% versus 79.6%). Minilaparotomy is feasible, safe, and favorable in terms of early oncologic outcome in patients with transverse colon cancer as well as those with sigmoid colon cancer.

2015 ◽  
Vol 87 (2) ◽  
pp. 167
Author(s):  
Yusuke Yagihashi ◽  
Yoshitaka Arakaki

Urethral recurrence arising from a primary colorectal adenocarcinoma is rare. Here, we report a case of urethral recurrence of sigmoid colon cancer, which developed after cysto-prostato-sigmoidectomy for sigmoid colon cancer invading the bladder. The patient underwent urethrectomy successfully and is currently tumor-free. Surgeons who follow patients with colorectal cancer invading the bladder should be aware of this case. The early detection of recurrence improves the chances for disease-free survival.


1994 ◽  
Vol 55 (5) ◽  
pp. 1233-1238
Author(s):  
Nobuaki SAKAMOTO ◽  
Kozaburo KIMURA ◽  
Yasuhisa KOYANAGI ◽  
Tatsuya AOKI ◽  
Atsushi NAKAJIMA ◽  
...  

2009 ◽  
Vol 17 (1) ◽  
pp. 25-28 ◽  
Author(s):  
Tatsuomi Miyauchi ◽  
Kazuhiko Yoshimatsu ◽  
Hajime Yokomizo ◽  
Gakuji Osawa ◽  
Kenji Ogawa

2014 ◽  
Vol 39 (5) ◽  
pp. 1001-1006
Author(s):  
Tomohide Mukogawa ◽  
Akihiko Watanabe ◽  
Yasuko Tsuji ◽  
Kota Nakamura ◽  
Saiho Ko ◽  
...  

2021 ◽  
Author(s):  
Shao-Qing Niu ◽  
Rong-Zhen Li ◽  
Yan Yuan ◽  
Wei-Hao Xie ◽  
Qiao-Xuan Wang ◽  
...  

Abstract Background: Patients with locally advanced sigmoid colon cancer (LASCC) have limited treatment options and a dismal prognosis with poor quality of life. This prospective study aimed to further evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy (NACRT) followed by surgery as treatment for select patients with unresectable LASCC.Methods: We studied patients with unresectable LASCC who received NACRT between November 2010 and April 2019. The NACRT regimen consisted of intensity modulated radiotherapy (IMRT) of 50 Gy to the gross tumor and positive lymphoma nodes and 45 Gy to the clinical target volume. Capecitabine‑based chemotherapy was administered every 3 weeks. Surgery was scheduled 6–8 weeks after radiotherapy.Results: Seventy‑two patients were enrolled in this study. Patients had a regular follow-up (median, 41.1 months; range, 8.3–116.5 months). Seventy‑one patients completed NACRT, and sixty-five completed surgery. Resection with microscopically negative margins (R0 resection) was achieved in 64 patients (88.9%). Pathologic complete response was observed in 15 patients (23.1%), and multivisceral resection was necessary in 38 patients (58.3%). The cumulative probability of 3-year overall survival and disease‑free survival were 75.8% and 70.7%, respectively.Conclusion: For patients with unresectable LASCC, neoadjuvant chemoradiotherapy is feasible, surgery can be performed safely and may result in increased survival and organ preservation rates.


Videoscopy ◽  
2012 ◽  
Vol 22 (4) ◽  
Author(s):  
Takehiro Hachisuka ◽  
Takashi Kinoshita ◽  
Nobuhiko Kurata ◽  
Masayuki Tsutsuyama ◽  
Shinichi Umeda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document